[Journal logo]

Volume 67 
Part 10 
Pages o2623-o2624  
October 2011  

Received 7 September 2011
Accepted 8 September 2011
Online 14 September 2011

Key indicators
Single-crystal X-ray study
T = 100 K
Mean [sigma](C-C) = 0.002 Å
R = 0.034
wR = 0.091
Data-to-parameter ratio = 14.8
Details
Open access

Ethyl 1-(4-methylphenyl)-5-phenyl-4-phenylsulfonyl-1H-pyrazole-3-carboxylate

aDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia,bDepartment of Chemistry, University of Malaya, 50603 Kuala Lumpur, Malaysia, and cChemistry Department, Faculty of, Science, King Abdulaziz University, PO Box 80203 Jeddah, Saudi Arabia
Correspondence e-mail: Edward.Tiekink@gmail.com

The title compound, C25H22N2O4S, features a tetra-substituted pyrazole ring. The dihedral angles formed between the five-membered ring (r.m.s. deviation = 0.007 Å) and the N- and C-bound phenyl rings are 48.10 (7) and 72.01 (7) °, respectively, indicating that the planes through the residues are significantly twisted from the plane through the heterocycle. The ester-CO2 group is also twisted out of this plane, with an O-C-C-N torsion angle of -29.04 (11)°. The sulfonyl-O atoms lie to one side of the pyrazole plane and the sulfonylphenyl ring to the other. The dihedral angle between the two ring planes is 70.63 (7) °. Supramolecular arrays are formed in the crystal structure sustained by C-H...O and C-H...[pi](pyrazole) interactions and methyl-C-H...[pi](N-bound benzene) contacts.

Related literature

For background to the chemistry and biological activity of pyrazole derivatives, see: Abdel-Wahab et al. (2009[Abdel-Wahab, B. F., Abdel-Aziz, H. A. & Ahmed, E. M. (2009). Monatsh. Chem. 140, 601-605.]); Abdel-Aziz et al. (2009[Abdel-Aziz, H. A., Gamal-Eldeen, A. M., Hamdy, N. A. & Fakhr, I. M. I. (2009). Arch. Pharm. 342, 230-237.], 2010[Abdel-Aziz, H. A., El-Zahabi, H. S. A. & Dawood, K. M. (2010). Eur. J. Med. Chem. 45, 2427-2432.]).

[Scheme 1]

Experimental

Crystal data
  • C25H22N2O4S

  • Mr = 446.51

  • Triclinic, [P \overline 1]

  • a = 7.2440 (3) Å

  • b = 11.0798 (5) Å

  • c = 14.8247 (5) Å

  • [alpha] = 68.818 (4)°

  • [beta] = 87.773 (3)°

  • [gamma] = 81.241 (4)°

  • V = 1096.36 (8) Å3

  • Z = 2

  • Cu K[alpha] radiation

  • [mu] = 1.60 mm-1

  • T = 100 K

  • 0.40 × 0.30 × 0.20 mm

Data collection
  • Agilent SuperNova Dual diffractometer with Atlas detector

  • Absorption correction: multi-scan (CrysAlis PRO; Agilent, 2010[Agilent (2010). CrysAlis PRO. Agilent Technologies, Yarnton, England.]) Tmin = 0.566, Tmax = 0.740

  • 7378 measured reflections

  • 4304 independent reflections

  • 4106 reflections with I > 2[sigma](I)

  • Rint = 0.014

Refinement
  • R[F2 > 2[sigma](F2)] = 0.034

  • wR(F2) = 0.091

  • S = 0.85

  • 4304 reflections

  • 290 parameters

  • H-atom parameters constrained

  • [Delta][rho]max = 0.35 e Å-3

  • [Delta][rho]min = -0.42 e Å-3

Table 1
Hydrogen-bond geometry (Å, °)

Cg1 and Cg2 are the centroids of the N1,N2,C4-C6 and C19-C24 rings, respectively.

D-H...A D-H H...A D...A D-H...A
C9-H9...O1i 0.95 2.45 3.2392 (19) 140
C16-H16...O2ii 0.95 2.49 3.3928 (18) 158
C17-H17...O1iii 0.95 2.50 3.3895 (18) 157
C18-H18...O2iii 0.95 2.58 3.4031 (17) 145
C23-H23...O4iv 0.95 2.59 3.3155 (18) 133
C15-H15...Cg1i 0.95 2.80 3.6781 (15) 154
C25-H25c...Cg2v 0.98 2.64 3.5649 (16) 157
Symmetry codes: (i) x+1, y, z; (ii) -x+2, -y+1, -z; (iii) -x+1, -y+1, -z; (iv) -x+1, -y+1, -z+1; (v) -x+2, -y, -z+1.

Data collection: CrysAlis PRO (Agilent, 2010[Agilent (2010). CrysAlis PRO. Agilent Technologies, Yarnton, England.]); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); molecular graphics: ORTEP-3 (Farrugia, 1997[Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.]) and DIAMOND (Brandenburg, 2006[Brandenburg, K. (2006). DIAMOND. Crystal Impact GbR, Bonn, Germany.]); software used to prepare material for publication: publCIF (Westrip, 2010[Westrip, S. P. (2010). J. Appl. Cryst. 43, 920-925.]).


Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: BT5639 ).


Acknowledgements

The authors acknowledge the research center, College of Pharmacy, and Deanship of Scientific Research, King Saud University, for financial support of this project. The University of Malaya is also thanked for support of the crystallographic facility.

References

Abdel-Aziz, H. A., El-Zahabi, H. S. A. & Dawood, K. M. (2010). Eur. J. Med. Chem. 45, 2427-2432.  [ISI] [ChemPort] [PubMed]
Abdel-Aziz, H. A., Gamal-Eldeen, A. M., Hamdy, N. A. & Fakhr, I. M. I. (2009). Arch. Pharm. 342, 230-237.  [ChemPort]
Abdel-Wahab, B. F., Abdel-Aziz, H. A. & Ahmed, E. M. (2009). Monatsh. Chem. 140, 601-605.  [ChemPort]
Agilent (2010). CrysAlis PRO. Agilent Technologies, Yarnton, England.
Brandenburg, K. (2006). DIAMOND. Crystal Impact GbR, Bonn, Germany.
Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.  [CrossRef] [details]
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [details]
Westrip, S. P. (2010). J. Appl. Cryst. 43, 920-925.  [ISI] [CrossRef] [ChemPort] [details]


Acta Cryst (2011). E67, o2623-o2624   [ doi:10.1107/S1600536811036580 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.